Arrowhead Pharmaceuticals, Inc. (ARWR)
USD 12.34
(4.66%)
USD 12.34
(4.66%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 445.73 Million USD | 5.69% |
| 2022 | 421.73 Million USD | 46.78% |
| 2021 | 287.32 Million USD | 58.61% |
| 2020 | 181.15 Million USD | 68.35% |
| 2019 | 107.6 Million USD | 49.29% |
| 2018 | 72.07 Million USD | 5.37% |
| 2017 | 68.4 Million USD | -14.34% |
| 2016 | 79.85 Million USD | -17.13% |
| 2015 | 96.35 Million USD | 87.91% |
| 2014 | 51.27 Million USD | 117.55% |
| 2013 | 23.57 Million USD | 11.0% |
| 2012 | 21.23 Million USD | 109.71% |
| 2011 | 10.12 Million USD | 7.47% |
| 2010 | 9.42 Million USD | -59.91% |
| 2009 | 23.5 Million USD | -35.27% |
| 2008 | 36.3 Million USD | -5.54% |
| 2007 | 38.43 Million USD | 76.01% |
| 2006 | 21.83 Million USD | 119.38% |
| 2005 | 9.95 Million USD | 235.68% |
| 2004 | 2.96 Million USD | 3039.83% |
| 2003 | 94.43 Thousand USD | -93.34% |
| 2002 | 1.41 Million USD | 1197.94% |
| 2001 | 109.28 Thousand USD | -17.22% |
| 2000 | 132.01 Thousand USD | 46.1% |
| 1999 | 90.36 Thousand USD | 31.17% |
| 1998 | 68.88 Thousand USD | -65.25% |
| 1997 | 198.23 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 171.35 Million USD | 44.77% |
| 2024 Q1 | 140.09 Million USD | 12.59% |
| 2024 Q2 | 121.66 Million USD | -13.16% |
| 2023 Q1 | 104.68 Million USD | -9.29% |
| 2023 Q4 | 124.42 Million USD | 4.98% |
| 2023 Q2 | 98.1 Million USD | -6.28% |
| 2023 Q3 | 118.52 Million USD | 20.82% |
| 2023 FY | 445.73 Million USD | 5.69% |
| 2022 Q3 | 105.32 Million USD | -4.47% |
| 2022 Q4 | 115.4 Million USD | 9.57% |
| 2022 Q1 | 90.76 Million USD | -12.03% |
| 2022 Q2 | 110.25 Million USD | 21.48% |
| 2022 FY | 421.73 Million USD | 46.78% |
| 2021 Q4 | 103.16 Million USD | 32.67% |
| 2021 Q1 | 45.35 Million USD | -21.46% |
| 2021 FY | 287.32 Million USD | 58.61% |
| 2021 Q2 | 61.04 Million USD | 34.58% |
| 2021 Q3 | 77.75 Million USD | 27.38% |
| 2020 Q1 | 34.3 Million USD | 1.94% |
| 2020 Q3 | 43.32 Million USD | -5.35% |
| 2020 FY | 181.15 Million USD | 68.35% |
| 2020 Q4 | 57.75 Million USD | 33.31% |
| 2020 Q2 | 45.76 Million USD | 33.41% |
| 2019 Q1 | 23.71 Million USD | 5.74% |
| 2019 Q3 | 24.1 Million USD | -7.79% |
| 2019 FY | 107.6 Million USD | 49.29% |
| 2019 Q2 | 26.13 Million USD | 10.23% |
| 2019 Q4 | 33.65 Million USD | 39.64% |
| 2018 Q1 | 17.32 Million USD | -8.65% |
| 2018 FY | 72.07 Million USD | 5.37% |
| 2018 Q3 | 16.64 Million USD | 6.14% |
| 2018 Q4 | 22.42 Million USD | 34.7% |
| 2018 Q2 | 15.68 Million USD | -9.46% |
| 2017 Q3 | 15.05 Million USD | -0.39% |
| 2017 Q1 | 19.26 Million USD | -2.57% |
| 2017 FY | 68.4 Million USD | -14.34% |
| 2017 Q4 | 18.96 Million USD | 25.95% |
| 2017 Q2 | 15.11 Million USD | -21.55% |
| 2016 Q2 | 21.3 Million USD | 9.92% |
| 2016 Q4 | 19.77 Million USD | 2.04% |
| 2016 Q1 | 19.38 Million USD | -23.3% |
| 2016 FY | 79.85 Million USD | -17.13% |
| 2016 Q3 | 19.38 Million USD | -9.05% |
| 2015 Q2 | 29.67 Million USD | 17.36% |
| 2015 FY | 96.35 Million USD | 87.91% |
| 2015 Q1 | 25.28 Million USD | 25.02% |
| 2015 Q3 | 16.11 Million USD | -45.69% |
| 2015 Q4 | 25.27 Million USD | 56.81% |
| 2014 Q1 | 7.05 Million USD | -12.31% |
| 2014 Q3 | 12.74 Million USD | 13.22% |
| 2014 Q4 | 20.22 Million USD | 58.71% |
| 2014 FY | 51.27 Million USD | 117.55% |
| 2014 Q2 | 11.25 Million USD | 59.59% |
| 2013 Q1 | 4.96 Million USD | -8.36% |
| 2013 Q2 | 5.43 Million USD | 9.36% |
| 2013 Q3 | 5.12 Million USD | -5.68% |
| 2013 Q4 | 8.04 Million USD | 56.92% |
| 2013 FY | 23.57 Million USD | 11.0% |
| 2012 FY | 21.23 Million USD | 109.71% |
| 2012 Q3 | 6.85 Million USD | 39.81% |
| 2012 Q1 | 4.06 Million USD | 39.49% |
| 2012 Q2 | 4.9 Million USD | 20.6% |
| 2012 Q4 | 5.42 Million USD | -20.85% |
| 2011 FY | 10.12 Million USD | 7.47% |
| 2011 Q4 | 2.91 Million USD | 64.54% |
| 2011 Q3 | 1.77 Million USD | -2.29% |
| 2011 Q2 | 1.81 Million USD | -69.83% |
| 2011 Q1 | 6 Million USD | 137.42% |
| 2010 Q4 | 2.52 Million USD | 10.05% |
| 2010 FY | 9.42 Million USD | -59.91% |
| 2010 Q3 | 2.29 Million USD | 0.49% |
| 2010 Q2 | 2.28 Million USD | -0.93% |
| 2010 Q1 | 2.3 Million USD | -37.89% |
| 2009 Q4 | 3.71 Million USD | -25.03% |
| 2009 FY | 23.5 Million USD | -35.27% |
| 2009 Q1 | 9.37 Million USD | -24.27% |
| 2009 Q2 | 5.45 Million USD | -41.85% |
| 2009 Q3 | 4.95 Million USD | -9.08% |
| 2008 FY | 36.3 Million USD | -5.54% |
| 2008 Q4 | 12.38 Million USD | 24.18% |
| 2008 Q3 | 9.97 Million USD | 34.61% |
| 2008 Q1 | 6.96 Million USD | -41.23% |
| 2008 Q2 | 7.4 Million USD | 6.42% |
| 2007 FY | 38.43 Million USD | 76.01% |
| 2007 Q2 | 8.43 Million USD | 88.12% |
| 2007 Q1 | 4.48 Million USD | -49.03% |
| 2007 Q3 | 13.67 Million USD | 62.06% |
| 2007 Q4 | 11.84 Million USD | -13.38% |
| 2006 FY | 21.83 Million USD | 119.38% |
| 2006 Q1 | 4.3 Million USD | 89.55% |
| 2006 Q2 | 4 Million USD | -7.03% |
| 2006 Q3 | 4.72 Million USD | 18.15% |
| 2006 Q4 | 8.79 Million USD | 86.06% |
| 2005 Q3 | 3.52 Million USD | 68.33% |
| 2005 Q4 | 2.27 Million USD | -35.64% |
| 2005 Q1 | 2.09 Million USD | 26.26% |
| 2005 Q2 | 2.09 Million USD | 0.2% |
| 2005 FY | 9.95 Million USD | 235.68% |
| 2004 Q4 | 1.65 Million USD | 161.71% |
| 2004 Q3 | 633.21 Thousand USD | 62.81% |
| 2004 Q1 | 142.52 Thousand USD | 848.0% |
| 2004 Q2 | 388.93 Thousand USD | 172.9% |
| 2004 FY | 2.96 Million USD | 3039.83% |
| 2003 FY | 94.43 Thousand USD | -93.34% |
| 2003 Q4 | 15.03 Thousand USD | -1.73% |
| 2003 Q3 | 15.29 Thousand USD | -49.55% |
| 2003 Q2 | 30.32 Thousand USD | -10.24% |
| 2003 Q1 | 33.78 Thousand USD | -97.44% |
| 2002 Q4 | 1.31 Million USD | 2585.13% |
| 2002 FY | 1.41 Million USD | 1197.94% |
| 2002 Q1 | 27.03 Thousand USD | 9.81% |
| 2002 Q2 | 22.96 Thousand USD | -15.05% |
| 2002 Q3 | 49.13 Thousand USD | 113.92% |
| 2001 Q3 | 18.66 Thousand USD | -27.14% |
| 2001 FY | 109.28 Thousand USD | -17.22% |
| 2001 Q2 | 25.61 Thousand USD | -36.55% |
| 2001 Q1 | 40.37 Thousand USD | 16.3% |
| 2001 Q4 | 24.62 Thousand USD | 31.92% |
| 2000 Q2 | 31.85 Thousand USD | -15.44% |
| 2000 Q1 | 37.66 Thousand USD | 88.33% |
| 2000 FY | 132.01 Thousand USD | 46.1% |
| 2000 Q3 | 27.78 Thousand USD | -12.77% |
| 2000 Q4 | 34.71 Thousand USD | 24.95% |
| 1999 FY | 90.36 Thousand USD | 31.17% |
| 1999 Q2 | 20 Thousand USD | 0.01% |
| 1999 Q4 | 20 Thousand USD | -91.3% |
| 1999 Q3 | 230 Thousand USD | 1050.0% |
| 1999 Q1 | 19.99 Thousand USD | 0.0% |
| 1998 Q4 | 19.99 Thousand USD | 299.99% |
| 1998 Q3 | -10 Thousand USD | -150.0% |
| 1998 FY | 68.88 Thousand USD | -65.25% |
| 1998 Q2 | 20 Thousand USD | 0.0% |
| 1997 FY | 198.23 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Agenus Inc. | 78.18 Million USD | -470.12% |
| Immix Biopharma, Inc. | 16.14 Million USD | -2661.501% |
| Keros Therapeutics, Inc. | 169.27 Million USD | -163.318% |
| Caribou Biosciences, Inc. | 150.53 Million USD | -196.1% |
| Madrigal Pharmaceuticals, Inc. | 380.49 Million USD | -17.146% |
| MiMedx Group, Inc. | 229.72 Million USD | -94.029% |
| Novavax, Inc. | 779.12 Million USD | 42.79% |
| Seer, Inc. | 110.49 Million USD | -303.418% |
| Acelyrin, Inc. | 422.06 Million USD | -5.609% |
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | -164.633% |
| IO Biotech, Inc. | 91.44 Million USD | -387.448% |
| Ardelyx, Inc. | 169.93 Million USD | -162.295% |
| C4 Therapeutics, Inc. | 159.78 Million USD | -178.957% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -3104.518% |
| Fortress Biotech, Inc. | 200.19 Million USD | -122.651% |
| Fortress Biotech, Inc. | 200.19 Million USD | -122.651% |
| Geron Corporation | 70.44 Million USD | -532.781% |
| HOOKIPA Pharma Inc. | 32.74 Million USD | -1261.195% |
| Incyte Corporation | 1.19 Billion USD | 62.559% |
| Innoviva, Inc. | 132.15 Million USD | -237.286% |
| Kintara Therapeutics, Inc. | 8.45 Million USD | -5174.37% |
| ChromaDex Corporation | 56.37 Million USD | -690.608% |
| Ligand Pharmaceuticals Incorporated | 84.32 Million USD | -428.607% |
| MEI Pharma, Inc. | 34.78 Million USD | -1181.406% |
| NextCure, Inc. | 67.63 Million USD | -559.014% |
| Onconetix, Inc. | 34.9 Million USD | -1176.912% |
| Oncternal Therapeutics, Inc. | 12.74 Million USD | -3397.074% |
| GlycoMimetics, Inc. | 39.28 Million USD | -1034.615% |
| IDEAYA Biosciences, Inc. | 157.81 Million USD | -182.445% |
| Vaxcyte, Inc. | 468.04 Million USD | 4.765% |
| Precigen, Inc. | 84.18 Million USD | -429.498% |
| Pharming Group N.V. | 225.49 Million USD | -97.674% |
| ContextLogic Inc. | 387 Million USD | -15.178% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | -2254.784% |
| Pyxis Oncology, Inc. | 82.19 Million USD | -442.286% |
| Rigel Pharmaceuticals, Inc. | 130.26 Million USD | -242.182% |
| AlloVir, Inc. | 180.93 Million USD | -146.355% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -1733.81% |
| Marinus Pharmaceuticals, Inc. | 160.54 Million USD | -177.649% |
| Salarius Pharmaceuticals, Inc. | 12.89 Thousand USD | -3456833.457% |
| Summit Therapeutics Inc. | 87.68 Million USD | -408.333% |
| Syndax Pharmaceuticals, Inc. | 229.95 Million USD | -93.837% |
| Sensei Biotherapeutics, Inc. | 37.06 Million USD | -1102.614% |
| Senti Biosciences, Inc. | 94.7 Million USD | -370.658% |
| BioXcel Therapeutics, Inc. | 171.9 Million USD | -159.297% |
| Alaunos Therapeutics, Inc. | 29.46 Million USD | -1412.562% |
| Entrada Therapeutics, Inc. | 132.17 Million USD | -237.232% |
| Psyence Biomedical Ltd. | 2.75 Million USD | -16099.282% |
| Outlook Therapeutics, Inc. | 53.12 Million USD | -739.013% |
| Chimerix, Inc. | 93.38 Million USD | -377.291% |
| PDS Biotechnology Corporation | 43.04 Million USD | -935.508% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -2453.342% |
| CRISPR Therapeutics AG | 463.49 Million USD | 3.831% |
| Wave Life Sciences Ltd. | 181.3 Million USD | -145.855% |
| Phathom Pharmaceuticals, Inc. | 167.82 Million USD | -165.593% |
| Pieris Pharmaceuticals, Inc. | 72.56 Million USD | -514.25% |
| CARGO Therapeutics, Inc. Common Stock | 96.71 Million USD | -360.901% |
| Precision BioSciences, Inc. | 92.46 Million USD | -382.071% |
| Dyadic International, Inc. | 9.15 Million USD | -4770.008% |
| Elevation Oncology, Inc. | 45.44 Million USD | -880.827% |
| Eton Pharmaceuticals, Inc. | 22.25 Million USD | -1903.042% |
| Akebia Therapeutics, Inc. | 201.11 Million USD | -121.633% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 75.238% |
| Aptorum Group Limited | 10.56 Thousand USD | -4218497.388% |
| Bicycle Therapeutics plc | 216.92 Million USD | -105.483% |
| Telomir Pharmaceuticals, Inc. Common Stock | 3.94 Million USD | -11207.244% |
| Clearside Biomedical, Inc. | 32.71 Million USD | -1262.485% |
| Inhibikase Therapeutics, Inc. | 6.73 Million USD | -6521.223% |
| GT Biopharma, Inc. | 13.57 Million USD | -3183.272% |
| Alkermes plc | 996.24 Million USD | 55.258% |
| Verrica Pharmaceuticals Inc. | 70.59 Million USD | -531.409% |
| Jaguar Health, Inc. | 42.01 Million USD | -960.9% |
| VistaGen Therapeutics, Inc. | 34.08 Million USD | -1207.722% |
| AbCellera Biologics Inc. | 275.23 Million USD | -61.95% |
| PureTech Health plc | 144.59 Million USD | -208.262% |
| TransCode Therapeutics, Inc. | 19.41 Million USD | -2195.423% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -94.917% |
| SELLAS Life Sciences Group, Inc. | 37.86 Million USD | -1077.05% |
| Barinthus Biotherapeutics plc | 84.71 Million USD | -426.154% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -1733.81% |
| Aadi Bioscience, Inc. | 93.47 Million USD | -376.836% |
| AnaptysBio, Inc. | 181.56 Million USD | -145.493% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | -1217.034% |
| ESSA Pharma Inc. | 32.13 Million USD | -1287.115% |
| Molecular Templates, Inc. | 63.09 Million USD | -606.499% |
| Scopus BioPharma Inc. | 11.71 Million USD | -3704.88% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | -10.45% |
| Vaxxinity, Inc. | 56.05 Million USD | -695.235% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | -779.287% |
| Sol-Gel Technologies Ltd. | 30.85 Million USD | -1344.431% |
| Janux Therapeutics, Inc. | 81.06 Million USD | -449.872% |
| Structure Therapeutics Inc. | 102.77 Million USD | -333.702% |
| Longboard Pharmaceuticals, Inc. | 56.75 Million USD | -685.315% |
| Stoke Therapeutics, Inc. | 123.55 Million USD | -260.766% |
| ImmuCell Corporation | 9.61 Million USD | -4534.712% |
| Lantern Pharma Inc. | 17.87 Million USD | -2393.275% |
| VYNE Therapeutics Inc. | 29.68 Million USD | -1401.708% |
| Ocuphire Pharma, Inc. | 29.6 Million USD | -1405.563% |
| Opthea Limited | 191.96 Million USD | -132.194% |
| Avidity Biosciences, Inc. | 245.15 Million USD | -81.816% |
| Syros Pharmaceuticals, Inc. | 30.77 Million USD | -1348.562% |
| Fate Therapeutics, Inc. | 254.04 Million USD | -75.457% |
| Inhibrx Biosciences, Inc. | 219.83 Million USD | -102.764% |
| Catalyst Pharmaceuticals, Inc. | 259.42 Million USD | -71.817% |
| Orchestra BioMed Holdings, Inc. | 54.08 Million USD | -724.218% |
| Alzamend Neuro, Inc. | 9.93 Million USD | -4385.338% |
| Rocket Pharmaceuticals, Inc. | 259.65 Million USD | -71.662% |
| Aptose Biosciences Inc. | 52.35 Million USD | -751.358% |
| ZyVersa Therapeutics, Inc. | 14.41 Million USD | -2993.167% |
| Soligenix, Inc. | 7.79 Million USD | -5618.058% |
| Century Therapeutics, Inc. | 56.07 Million USD | -694.951% |
| Kura Oncology, Inc. | 165.8 Million USD | -168.834% |
| TScan Therapeutics, Inc. | 114.5 Million USD | -289.266% |
| Intensity Therapeutics, Inc. | 8.31 Million USD | -5258.06% |
| Ocean Biomedical, Inc. | 2.48 Million USD | -17861.396% |
| CytomX Therapeutics, Inc. | 107.69 Million USD | -313.877% |
| Autolus Therapeutics plc | 196.72 Million USD | -126.578% |
| Mineralys Therapeutics, Inc. | 84.65 Million USD | -426.521% |
| EyePoint Pharmaceuticals, Inc. | 116.45 Million USD | -282.761% |
| Eterna Therapeutics Inc. | 19.38 Million USD | -2199.629% |
| Adaptive Biotechnologies Corporation | 321.75 Million USD | -38.532% |
| GRI Bio, Inc. | 11.33 Million USD | -3834.131% |
| Xenetic Biosciences, Inc. | 7.05 Million USD | -6217.402% |
| Tenaya Therapeutics, Inc. | 131.19 Million USD | -239.757% |
| IGM Biosciences, Inc. | 265.59 Million USD | -67.828% |
| INmune Bio, Inc. | 29.89 Million USD | -1390.959% |
| Heron Therapeutics, Inc. | 172.55 Million USD | -158.317% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -1005.655% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -2689.454% |
| Entero Therapeutics, Inc. | 15.74 Million USD | -2731.595% |
| Milestone Pharmaceuticals Inc. | 62.09 Million USD | -617.796% |
| X4 Pharmaceuticals, Inc. | 107.52 Million USD | -314.554% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -61.679% |
| Coherus BioSciences, Inc. | 301.45 Million USD | -47.864% |
| Verastem, Inc. | 92.08 Million USD | -384.055% |
| Abeona Therapeutics Inc. | 17.93 Million USD | -2384.737% |
| Pliant Therapeutics, Inc. | 185.72 Million USD | -139.998% |
| Tonix Pharmaceuticals Holding Corp. | 121.4 Million USD | -267.143% |
| Histogen Inc. | 14.27 Million USD | -3023.157% |
| Aprea Therapeutics, Inc. | 16.04 Million USD | -2677.499% |
| Surrozen, Inc. | 18.55 Million USD | -2302.895% |
| Organovo Holdings, Inc. | 14.91 Million USD | -2888.515% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -8656.706% |
| Ovid Therapeutics Inc. | 59.67 Million USD | -646.964% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | -1637.969% |
| CASI Pharmaceuticals, Inc. | 47 Million USD | -848.256% |
| Cadrenal Therapeutics, Inc. Common Stock | 7.63 Million USD | -5739.724% |
| Centessa Pharmaceuticals plc | 178.13 Million USD | -150.223% |
| Hepion Pharmaceuticals, Inc. | 48.44 Million USD | -820.033% |
| Arcturus Therapeutics Holdings Inc. | 245 Million USD | -81.93% |
| BioRestorative Therapies, Inc. | 15.36 Million USD | -2800.692% |
| Apollomics, Inc. | 54.14 Million USD | -723.304% |
| Amarin Corporation plc | 272.35 Million USD | -63.659% |
| Mesoblast Limited | 5.9 Million USD | -7452.304% |
| Turnstone Biologics Corp. | 78.33 Million USD | -468.992% |
| Kymera Therapeutics, Inc. | 244.12 Million USD | -82.588% |
| Synaptogenix, Inc. | 8.31 Million USD | -5261.376% |
| Tiziana Life Sciences Ltd | 14.58 Million USD | -2955.923% |
| Aurinia Pharmaceuticals Inc. | 253.05 Million USD | -76.142% |
| BriaCell Therapeutics Corp. | 33.33 Million USD | -1237.342% |
| Monopar Therapeutics Inc. | 8.83 Million USD | -4947.278% |
| Exelixis, Inc. | 1.58 Billion USD | 71.909% |
| Better Therapeutics, Inc. | 38.26 Million USD | -1064.96% |
| Nurix Therapeutics, Inc. | 232.05 Million USD | -92.087% |
| Apellis Pharmaceuticals, Inc. | 855.2 Million USD | 47.879% |
| NLS Pharmaceutics AG | 11.8 Million USD | -3675.173% |
| Dermata Therapeutics, Inc. | 8.04 Million USD | -5442.679% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | -1386.137% |
| Gritstone bio, Inc. | 148.37 Million USD | -200.414% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -547.3% |
| TNF Pharmaceuticals, Inc. | 16.36 Million USD | -2624.517% |
| Avid Bioservices, Inc. | 25.99 Million USD | -1614.637% |
| Insmed Incorporated | 949.26 Million USD | 53.044% |
| Virpax Pharmaceuticals, Inc. | 15.68 Million USD | -2740.937% |
| MediWound Ltd. | 18.86 Million USD | -2262.397% |
| OmniAb, Inc. | 83.89 Million USD | -431.303% |
| Alector, Inc. | 248.8 Million USD | -79.153% |
| Seres Therapeutics, Inc. | 234.3 Million USD | -90.236% |
| Checkpoint Therapeutics, Inc. | 52.25 Million USD | -753.069% |
| Zai Lab Limited | 547.47 Million USD | 18.583% |
| Revance Therapeutics, Inc. | 398.65 Million USD | -11.81% |
| Aura Biosciences, Inc. | 84.99 Million USD | -424.452% |
| Lyell Immunopharma, Inc. | 247.13 Million USD | -80.36% |
| Immunic, Inc. | 99.22 Million USD | -349.227% |
| Tarsus Pharmaceuticals, Inc. | 159.01 Million USD | -180.317% |
| Veracyte, Inc. | 357.93 Million USD | -24.531% |
| InMed Pharmaceuticals Inc. | 9.01 Billion USD | 95.056% |
| FibroGen, Inc. | 398.11 Million USD | -11.962% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -3036.784% |
| Adial Pharmaceuticals, Inc. | 6.88 Million USD | -6371.261% |
| Sonnet BioTherapeutics Holdings, Inc. | 7.12 Million USD | -6155.315% |
| Jazz Pharmaceuticals plc | 3.25 Billion USD | 86.309% |
| Cyclacel Pharmaceuticals, Inc. | 25.87 Million USD | -1622.788% |
| Amylyx Pharmaceuticals, Inc. | 316.54 Million USD | -40.814% |
| TG Therapeutics, Inc. | 198.47 Million USD | -124.581% |
| Galecto, Inc. | 35.62 Million USD | -1151.121% |
| Calithera Biosciences, Inc. | 40.68 Million USD | -995.473% |
| Fortrea Holdings Inc. | 457.3 Million USD | 2.529% |
| KalVista Pharmaceuticals, Inc. | 54.27 Million USD | -721.211% |
| Aptevo Therapeutics Inc. | 28.87 Million USD | -1443.518% |
| XBiotech Inc. | 37.51 Million USD | -1088.315% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -547.3% |
| Lyra Therapeutics, Inc. | 20.64 Million USD | -2058.637% |
| Foghorn Therapeutics Inc. | 142.06 Million USD | -213.765% |
| Y-mAbs Therapeutics, Inc. | 99.07 Million USD | -349.899% |
| Theravance Biopharma, Inc. | 110.71 Million USD | -302.595% |
| Ultragenyx Pharmaceutical Inc. | 958.24 Million USD | 53.484% |
| Metagenomi, Inc. Common Stock | 28.84 Million USD | -1445.283% |
| BioCryst Pharmaceuticals, Inc. | 430.64 Million USD | -3.506% |
| Gain Therapeutics, Inc. | 22.3 Million USD | -1898.076% |
| Cartesian Therapeutics, Inc. | 110.86 Million USD | -302.047% |
| NexImmune, Inc. | 28.16 Million USD | -1482.451% |
| Creative Medical Technology Holdings, Inc. | 5.53 Million USD | -7958.962% |
| Marker Therapeutics, Inc. | 17.89 Million USD | -2391.193% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 84.167% |
| Chemomab Therapeutics Ltd. | 25.45 Million USD | -1650.803% |
| RAPT Therapeutics, Inc. | 127.06 Million USD | -250.803% |
| Ainos, Inc. | 12.95 Million USD | -3341.277% |
| Pluri Inc. | 22.48 Million USD | -1882.816% |
| Prothena Corporation plc | 282.4 Million USD | -57.836% |
| Adaptimmune Therapeutics plc | 200.02 Million USD | -122.844% |
| Celularity Inc. | 215.05 Million USD | -107.264% |
| Rallybio Corporation | 78.93 Million USD | -464.71% |
| Cue Biopharma, Inc. | 19.54 Million USD | -2180.918% |
| MeiraGTx Holdings plc | 151.07 Million USD | -195.038% |
| Omeros Corporation | 94.75 Million USD | -370.43% |
| Humacyte, Inc. | 23.49 Million USD | -1796.995% |
| Immunocore Holdings plc | 308.04 Million USD | -44.701% |
| Cocrystal Pharma, Inc. | 3.39 Million USD | -13048.584% |
| Cidara Therapeutics, Inc. | 86.86 Million USD | -413.138% |
| Blueprint Medicines Corporation | 722.86 Million USD | 38.337% |
| CalciMedica, Inc. | 21.81 Million USD | -1943.072% |
| Cabaletta Bio, Inc. | 74.66 Million USD | -497.023% |
| Scholar Rock Holding Corporation | 171.29 Million USD | -160.216% |
| Sana Biotechnology, Inc. | 294.94 Million USD | -51.128% |
| Pulmatrix, Inc. | 22.03 Million USD | -1922.584% |
| Elicio Therapeutics, Inc. | 34.57 Million USD | -1189.189% |
| Vigil Neuroscience, Inc. | 88.86 Million USD | -401.583% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 19.187% |
| Adlai Nortye Ltd. American Depositary Shares | 72.55 Million USD | -514.377% |
| Cytokinetics, Incorporated | 173.61 Million USD | -156.743% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | -1195.032% |
| Nutriband Inc. | 5.73 Million USD | -7673.537% |
| Protara Therapeutics, Inc. | 43.61 Million USD | -922.028% |
| Vor Biopharma Inc. | 126.03 Million USD | -253.658% |
| Roivant Sciences Ltd. | 1.18 Billion USD | 62.517% |
| Evogene Ltd. | 27.79 Million USD | -1503.947% |
| ProKidney Corp. | 151.52 Million USD | -194.173% |
| Applied Therapeutics, Inc. | 74.17 Million USD | -500.926% |
| Hoth Therapeutics, Inc. | 7.69 Million USD | -5694.63% |
| BridgeBio Pharma, Inc. | 614.22 Million USD | 27.431% |
| CorMedix Inc. | 48.95 Million USD | -810.452% |
| BioLineRx Ltd. | 50.8 Million USD | -777.4% |
| Tango Therapeutics, Inc. | 150.7 Million USD | -195.778% |
| Galectin Therapeutics Inc. | 38.07 Million USD | -1070.774% |
| Atai Life Sciences N.V. | 125.78 Million USD | -254.364% |
| Renovaro Biosciences Inc. | 81.63 Million USD | -445.983% |
| Aerovate Therapeutics, Inc. | 81.4 Million USD | -447.528% |
| Zentalis Pharmaceuticals, Inc. | 252.55 Million USD | -76.493% |
| Sagimet Biosciences Inc. | 32.74 Million USD | -1261.445% |
| MediciNova, Inc. | 10.9 Million USD | -3989.231% |
| Praxis Precision Medicines, Inc. | 128.82 Million USD | -246.015% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -6040.031% |
| GeoVax Labs, Inc. | 6.02 Million USD | -7301.597% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 6.429% |
| Biomea Fusion, Inc. | 126.13 Million USD | -253.381% |
| PTC Therapeutics, Inc. | 1.31 Billion USD | 66.022% |
| Mereo BioPharma Group plc | 35.84 Million USD | -1143.616% |
| Cullinan Oncology, Inc. | 191.08 Million USD | -133.261% |
| Absci Corporation | 73.66 Million USD | -505.078% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -1516.043% |
| 4D Molecular Therapeutics, Inc. | 133.59 Million USD | -233.66% |
| Dyne Therapeutics, Inc. | 242.16 Million USD | -84.066% |
| Kiniksa Pharmaceuticals, Ltd. | 262.04 Million USD | -70.097% |
| Ventyx Biosciences, Inc. | 207.99 Million USD | -114.303% |
| Allakos Inc. | 196.05 Million USD | -127.352% |
| Imunon, Inc. | 20.31 Million USD | -2094.622% |
| Fulcrum Therapeutics, Inc. | 113.46 Million USD | -292.827% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | -20.923% |
| BioAtla, Inc. | 129.68 Million USD | -243.702% |
| NLS Pharmaceutics AG | 11.8 Million USD | -3675.173% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | -2713.463% |
| Allogene Therapeutics, Inc. | 84.91 Million USD | -424.903% |
| Larimar Therapeutics, Inc. | 41.75 Million USD | -967.429% |
| XOMA Corporation | 46.46 Million USD | -859.338% |
| Kezar Life Sciences, Inc. | 111.17 Million USD | -300.947% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -212.879% |
| aTyr Pharma, Inc. | 12.97 Million USD | -3334.294% |
| Aligos Therapeutics, Inc. | 103.65 Million USD | -330.016% |
| Akero Therapeutics, Inc. | 172.87 Million USD | -157.845% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | -74.961% |
| Eliem Therapeutics, Inc. | 37.4 Million USD | -1091.555% |
| EyeGate Pharmaceuticals, Inc. | 8.22 Million USD | -5319.417% |
| Akari Therapeutics, Plc | 16.8 Million USD | -2552.249% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -19501.71% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | -48.918% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -6524.385% |
| UroGen Pharma Ltd. | 138.88 Million USD | -220.933% |
| Sutro Biopharma, Inc. | 243 Million USD | -83.424% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -6027.287% |
| Orgenesis Inc. | 45.75 Million USD | -874.139% |
| Entera Bio Ltd. | 8.86 Million USD | -4930.892% |
| GH Research PLC | 41.22 Million USD | -981.309% |
| Lisata Therapeutics, Inc. | 25.7 Million USD | -1633.845% |
| Reneo Pharmaceuticals, Inc. | 83.05 Million USD | -436.69% |
| Xencor, Inc. | 306.97 Million USD | -45.202% |
| 60 Degrees Pharmaceuticals, Inc. | 4.93 Million USD | -8934.71% |
| Replimune Group, Inc. | 234.77 Million USD | -89.859% |
| Coeptis Therapeutics Holdings, Inc. | 20.48 Million USD | -2075.4% |
| Vanda Pharmaceuticals Inc. | 191.79 Million USD | -132.402% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -6524.385% |
| Portage Biotech Inc. | 18.19 Million USD | -2349.239% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -6040.031% |
| Olema Pharmaceuticals, Inc. | 104.96 Million USD | -324.669% |
| OncoCyte Corporation | 25.63 Million USD | -1638.647% |
| Qualigen Therapeutics, Inc. | 6.09 Million USD | -7212.43% |
| Processa Pharmaceuticals, Inc. | 11.45 Million USD | -3790.5% |
| Purple Biotech Ltd. | -22.46 Million USD | 2083.963% |
| CollPlant Biotechnologies Ltd. | 16.48 Million USD | -2604.715% |
| scPharmaceuticals Inc. | 65.17 Million USD | -583.876% |
| ProMIS Neurosciences, Inc. | 8.45 Million USD | -5173.287% |
| HilleVax, Inc. | 133.34 Million USD | -234.274% |
| NeuroSense Therapeutics Ltd. | 10.28 Million USD | -4233.855% |
| Tharimmune, Inc. | 9.45 Million USD | -4614.19% |
| Genprex, Inc. | 31.06 Million USD | -1335.058% |
| Neumora Therapeutics, Inc. Common Stock | 187.52 Million USD | -137.693% |
| Atossa Therapeutics, Inc. | 31.37 Million USD | -1320.585% |
| XTL Biopharmaceuticals Ltd. | 765 Thousand USD | -58166.275% |
| Virios Therapeutics, Inc. | 5.44 Million USD | -8083.287% |
| OKYO Pharma Limited | 8243.57 USD | -5406986.978% |
| Savara Inc. | 15.74 Million USD | -2730.975% |
| Curis, Inc. | 58.35 Million USD | -663.837% |
| Daré Bioscience, Inc. | 33.6 Million USD | -1226.227% |
| Carmell Therapeutics Corporation | 5.09 Million USD | -8652.834% |
| Titan Pharmaceuticals, Inc. | 7.46 Million USD | -5874.226% |
| Achieve Life Sciences, Inc. | 27.02 Million USD | -1549.534% |
| BeiGene, Ltd. | 3.28 Billion USD | 86.438% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | -2135.47% |
| Revolution Medicines, Inc. Warrant | 498.76 Million USD | 10.632% |
| Protagonist Therapeutics, Inc. | 153.65 Million USD | -190.095% |
| Erasca, Inc. | 141.52 Million USD | -214.953% |
| bluebird bio, Inc. | 240.23 Million USD | -85.544% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -9746.246% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 74.475% |
| DBV Technologies S.A. | 92.16 Million USD | -383.656% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -9746.246% |
| Moderna, Inc. | 6.39 Billion USD | 93.029% |
| Vincerx Pharma, Inc. | 42.6 Million USD | -946.11% |
| Fresh Tracks Therapeutics, Inc. | 14.36 Million USD | -3002.722% |
| Acrivon Therapeutics, Inc. Common Stock | 66.7 Million USD | -568.261% |
| Travere Therapeutics, Inc. | 472 Million USD | 5.565% |
| Monte Rosa Therapeutics, Inc. | 143.31 Million USD | -211.028% |
| Spruce Biosciences, Inc. | 62.08 Million USD | -617.981% |
| Celldex Therapeutics, Inc. | 43.41 Million USD | -926.713% |
| Cogent Biosciences, Inc. | 208.13 Million USD | -114.163% |
| MacroGenics, Inc. | 217.21 Million USD | -105.205% |
| RenovoRx, Inc. | 11.39 Million USD | -3811.346% |
| Adicet Bio, Inc. | 152.03 Million USD | -193.175% |
| Prime Medicine, Inc. | 186.63 Million USD | -138.823% |
| Aditxt, Inc. | 25.95 Million USD | -1617.626% |
| Adagene Inc. | 41.83 Million USD | -965.557% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -5997.552% |
| Quantum-Si incorporated | 111.65 Million USD | -299.195% |
| Maravai LifeSciences Holdings, Inc. | 171.85 Million USD | -159.376% |
| Acurx Pharmaceuticals, Inc. | 14.57 Million USD | -2957.649% |
| Voyager Therapeutics, Inc. | 35.82 Million USD | -1144.311% |
| SciSparc Ltd. | 9.01 Million USD | -4846.588% |
| Vericel Corporation | 142.04 Million USD | -213.811% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -5049.062% |
| Minerva Neurosciences, Inc. | 23.08 Million USD | -1830.551% |
| Generation Bio Co. | 144.46 Million USD | -208.539% |
| Astria Therapeutics, Inc. | 83.03 Million USD | -436.838% |
| Black Diamond Therapeutics, Inc. | 86.46 Million USD | -415.541% |
| Arcutis Biotherapeutics, Inc. | 295.72 Million USD | -50.729% |
| Invivyd, Inc. | 205.75 Million USD | -116.635% |
| Relay Therapeutics, Inc. | 72.15 Million USD | -517.715% |
| Quoin Pharmaceuticals, Ltd. | 9.37 Million USD | -4652.752% |
| Spero Therapeutics, Inc. | 75.25 Million USD | -492.31% |
| Artelo Biosciences, Inc. | 10.28 Million USD | -4233.013% |
| 2seventy bio, Inc. | 289.88 Million USD | -53.762% |
| ADMA Biologics, Inc. | 66.58 Million USD | -569.415% |
| Clene Inc. | 41.07 Million USD | -985.231% |
| Capricor Therapeutics, Inc. | 12.8 Million USD | -3380.176% |
| Boundless Bio, Inc. Common Stock | 54.79 Million USD | -713.448% |
| GeoVax Labs, Inc. | 6.02 Million USD | -7301.597% |
| Recursion Pharmaceuticals, Inc. | 352.04 Million USD | -26.613% |
| Citius Pharmaceuticals, Inc. | 36.73 Million USD | -1113.484% |
| Contineum Therapeutics, Inc. Class A Common Stock | 33.72 Million USD | -1221.564% |
| Relmada Therapeutics, Inc. | 103.7 Million USD | -329.825% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | -1267.753% |
| ALX Oncology Holdings Inc. | 170.27 Million USD | -161.77% |
| Vir Biotechnology, Inc. | 767.72 Million USD | 41.94% |
| Evaxion Biotech A/S | 22.27 Million USD | -1901.513% |
| Ocular Therapeutix, Inc. | 135.54 Million USD | -228.85% |
| Verve Therapeutics, Inc. | 234.88 Million USD | -89.771% |
| Trevena, Inc. | 38.41 Million USD | -1060.381% |
| Surrozen, Inc. | 18.55 Million USD | -2302.895% |
| Tyra Biosciences, Inc. | 79.94 Million USD | -457.555% |
| Cingulate Inc. | 22.75 Million USD | -1858.492% |
| Galmed Pharmaceuticals Ltd. | -7.49 Million USD | 6049.506% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -897.911% |
| Tenax Therapeutics, Inc. | 8.23 Million USD | -5313.41% |
| Terns Pharmaceuticals, Inc. | 102.55 Million USD | -334.619% |
| ACADIA Pharmaceuticals Inc. | 754.08 Million USD | 40.89% |
| Connect Biopharma Holdings Limited | 62.07 Million USD | -618.074% |
| Clearmind Medicine Inc. | 8.74 Million USD | -4999.178% |
| Kronos Bio, Inc. | 128.11 Million USD | -247.911% |
| Bolt Biotherapeutics, Inc. | 84.07 Million USD | -430.185% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -15097.384% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -342.081% |
| Statera Biopharma, Inc. | 28.82 Million USD | -1446.114% |
| ImmunityBio, Inc. | 362.87 Million USD | -22.836% |
| Korro Bio, Inc. | 84.53 Million USD | -427.287% |
| Kineta, Inc. | 21.15 Million USD | -2006.906% |
| BioVie Inc. | 31.95 Million USD | -1295.099% |
| Codexis, Inc. | 66.51 Million USD | -570.1% |
| Celularity Inc. | 215.05 Million USD | -107.264% |
| Crinetics Pharmaceuticals, Inc. | 226.62 Million USD | -96.688% |
| Celcuity Inc. | 66.23 Million USD | -573.01% |
| Virax Biolabs Group Limited | 6.54 Million USD | -6708.198% |
| Cibus, Inc. | 320.3 Million USD | -39.16% |
| Eledon Pharmaceuticals, Inc. | 43 Million USD | -936.598% |
| IN8bio, Inc. | 30.33 Million USD | -1369.285% |
| Kodiak Sciences Inc. | 277.32 Million USD | -60.73% |
| Annexon, Inc. | 143.72 Million USD | -210.136% |
| Adverum Biotechnologies, Inc. | 127.59 Million USD | -249.348% |
| Assembly Biosciences, Inc. | 22.9 Million USD | -1845.685% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -69546.406% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 42.824% |
| Eyenovia, Inc. | 25.4 Million USD | -1654.425% |
| Puma Biotechnology, Inc. | 140.31 Million USD | -217.669% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -7913.97% |
| Xilio Therapeutics, Inc. | 79.13 Million USD | -463.276% |
| Arcellx, Inc. | 200.19 Million USD | -122.647% |
| Cardiff Oncology, Inc. | 45.9 Million USD | -871.105% |
| Enanta Pharmaceuticals, Inc. | 216.41 Million USD | -105.968% |
| Regulus Therapeutics Inc. | 9.95 Million USD | -4376.619% |
| Moolec Science SA | 52.75 Million USD | -744.989% |
| Acumen Pharmaceuticals, Inc. | 61.13 Million USD | -629.067% |
| LAVA Therapeutics N.V. | 46.54 Million USD | -857.75% |
| Royalty Pharma plc | 862.4 Million USD | 48.315% |
| Atea Pharmaceuticals, Inc. | 94.07 Million USD | -373.825% |
| Greenwich LifeSciences, Inc. | 9.32 Million USD | -4678.553% |
| TFF Pharmaceuticals, Inc. | 22.62 Million USD | -1869.801% |
| Mersana Therapeutics, Inc. | 207.81 Million USD | -114.491% |
| Humacyte, Inc. | 23.49 Million USD | -1796.995% |
| 89bio, Inc. | 151.2 Million USD | -194.792% |
| PMV Pharmaceuticals, Inc. | 80.13 Million USD | -456.253% |
| Avenue Therapeutics, Inc. | 14.54 Million USD | -2965.591% |
| Genelux Corporation | 24.33 Million USD | -1731.67% |
| Trevi Therapeutics, Inc. | 33.92 Million USD | -1213.967% |
| Lexicon Pharmaceuticals, Inc. | 172.86 Million USD | -157.847% |
| Notable Labs, Ltd. | 14.77 Million USD | -2917.854% |
| Liquidia Corporation | 87.98 Million USD | -406.611% |
| Mustang Bio, Inc. | 48.5 Million USD | -819.026% |
| Immunovant, Inc. | 282.7 Million USD | -57.666% |
| Quantum-Si incorporated | 111.65 Million USD | -299.195% |
| Arbutus Biopharma Corporation | 22.54 Million USD | -1877.187% |
| DiaMedica Therapeutics Inc. | 21.26 Million USD | -1995.909% |
| Vera Therapeutics, Inc. | 102.01 Million USD | -336.946% |
| Acasti Pharma Inc. | 11.3 Million USD | -3844.226% |
| MiNK Therapeutics, Inc. | 22.92 Million USD | -1844.658% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -2689.454% |
| Xenon Pharmaceuticals Inc. | 46.54 Million USD | -857.709% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -39186.52% |
| NeuroBo Pharmaceuticals, Inc. | 15.88 Million USD | -2705.848% |
| Tempest Therapeutics, Inc. | 29.15 Million USD | -1428.748% |
| Soleno Therapeutics, Inc. | 41.38 Million USD | -977.076% |
| PepGen Inc. | 84.76 Million USD | -425.844% |
| Moleculin Biotech, Inc. | 29.63 Million USD | -1404.293% |
| United Therapeutics Corporation | 885.1 Million USD | 49.64% |
| Nuvectis Pharma, Inc. | 22.89 Million USD | -1846.705% |
| Solid Biosciences Inc. | 104.31 Million USD | -327.299% |
| BriaCell Therapeutics Corp. | 32.72 Million USD | -1262.047% |
| Immuneering Corporation | 58.41 Million USD | -663.08% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -8656.706% |
| Silo Pharma, Inc. | 3.92 Million USD | -11265.461% |
| Belite Bio, Inc | 31.66 Million USD | -1307.531% |
| XOMA Corporation | 46.46 Million USD | -859.338% |
| ARS Pharmaceuticals, Inc. | 67.55 Million USD | -559.862% |
| Bionomics Limited | 17.89 Billion USD | 97.509% |
| Apogee Therapeutics, Inc. | 93 Million USD | -379.272% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 1349.263% |
| uniQure N.V. | 285.08 Million USD | -56.352% |
| Cassava Sciences, Inc. | 105.95 Million USD | -320.677% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -5997.552% |
| Poseida Therapeutics, Inc. | 194.2 Million USD | -129.516% |
| Forte Biosciences, Inc. | 32.47 Million USD | -1272.47% |
| Anebulo Pharmaceuticals, Inc. | 8.3 Million USD | -5264.667% |
| Enlivex Therapeutics Ltd. | 29.39 Million USD | -1416.37% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -7913.97% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -3036.784% |
| FibroBiologics, Inc. Common Stock | 8.88 Million USD | -4914.479% |
| Altimmune, Inc. | 30.55 Million USD | -1358.754% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | -4.229% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 1349.263% |
| Compugen Ltd. | 43.97 Million USD | -913.707% |
| Peak Bio, Inc. | 1249.13 USD | -35683695.922% |
| Zevra Therapeutics, Inc. | 74.12 Million USD | -501.372% |
| Benitec Biopharma Inc. | 22.38 Million USD | -1891.498% |
| Spyre Therapeutics, Inc. | 243.18 Million USD | -83.288% |
| NKGen Biotech, Inc. Common Stock | 28.54 Million USD | -1461.633% |
| Zura Bio Limited | 62.63 Million USD | -611.608% |
| PolyPid Ltd. | 21.04 Million USD | -2018.019% |
| Aileron Therapeutics, Inc. | 16.27 Million USD | -2638.615% |
| NKGen Biotech, Inc. Warrants | 28.54 Million USD | -1461.633% |
| Instil Bio, Inc. | 85.78 Million USD | -419.598% |
| argenx SE | 1.53 Billion USD | 70.934% |
| Immunome, Inc. | 122.82 Million USD | -262.919% |
| Compass Therapeutics, Inc. | 48.47 Million USD | -819.557% |
| Verona Pharma plc | 67.15 Million USD | -563.78% |
| enGene Holdings Inc. Warrants | 25.88 Million USD | -1621.99% |
| Shattuck Labs, Inc. | 93.61 Million USD | -376.144% |
| CervoMed Inc. | 14.95 Million USD | -2879.97% |
| LENZ Therapeutics, Inc. | 70.7 Million USD | -530.436% |
| Plus Therapeutics, Inc. | 8.54 Million USD | -5116.959% |
| Dianthus Therapeutics, Inc. | 51 Million USD | -773.994% |
| Moolec Science SA | 52.75 Million USD | -744.989% |
| Enveric Biosciences, Inc. | 16.44 Million USD | -2609.904% |
| Inovio Pharmaceuticals, Inc. | 132.55 Million USD | -236.265% |
| Design Therapeutics, Inc. | 78.19 Million USD | -470.069% |
| Leap Therapeutics, Inc. | 87.04 Million USD | -412.1% |
| NeurAxis, Inc. | 8.82 Million USD | -4953.021% |
| Seelos Therapeutics, Inc. | 12.58 Million USD | -3441.812% |
| Lumos Pharma, Inc. | 38.66 Million USD | -1052.818% |
| Achilles Therapeutics plc | 75.25 Million USD | -492.302% |
| enGene Holdings Inc. Common Stock | 25.88 Million USD | -1621.99% |
| 180 Life Sciences Corp. | 13.47 Million USD | -3207.268% |
| Opiant Pharmaceuticals, Inc. | 26.5 Million USD | -1581.871% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -15097.384% |
| Nutriband Inc. | 5.73 Million USD | -7673.537% |
| ORIC Pharmaceuticals, Inc. | 110.78 Million USD | -302.362% |
| CG Oncology, Inc. Common stock | 55.65 Million USD | -700.922% |
| Fractyl Health, Inc. Common Stock | 50.87 Million USD | -776.073% |
| Rani Therapeutics Holdings, Inc. | 66.09 Million USD | -574.348% |
| MoonLake Immunotherapeutics | 54.12 Million USD | -723.562% |
| Palisade Bio, Inc. | 13.32 Million USD | -3246.374% |
| Tourmaline Bio, Inc. | 45.4 Million USD | -881.605% |
| Beam Therapeutics Inc. | 554.19 Million USD | 19.57% |
| Neurogene Inc. | 55.58 Million USD | -701.93% |
| Mirum Pharmaceuticals, Inc. | 248.48 Million USD | -79.379% |
| AEON Biopharma, Inc. | 48.42 Million USD | -820.393% |
| Sesen Bio, Inc. | 78.38 Million USD | -468.68% |
| Enliven Therapeutics, Inc. | 83.52 Million USD | -433.631% |
| Kiora Pharmaceuticals, Inc. | 12.58 Million USD | -3441.278% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 1.165% |
| Taysha Gene Therapies, Inc. | 87.89 Million USD | -407.153% |
| Athira Pharma, Inc. | 125.46 Million USD | -255.265% |
| Vaccinex, Inc. | 23.45 Million USD | -1800.392% |
| HCW Biologics Inc. | 21.02 Million USD | -2019.779% |
| XOMA Corporation | 46.46 Million USD | -859.338% |
| Nektar Therapeutics | 190.9 Million USD | -133.489% |
| Arvinas, Inc. | 480 Million USD | 7.138% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -19501.71% |
| Merus N.V. | 200.49 Million USD | -122.319% |
| Omega Therapeutics, Inc. | 103.35 Million USD | -331.268% |
| Quince Therapeutics, Inc. | 34.62 Million USD | -1187.513% |
| Rezolute, Inc. | 70.38 Million USD | -533.266% |
| Clene Inc. | 41.07 Million USD | -985.231% |
| Indaptus Therapeutics, Inc. | 16.37 Million USD | -2621.481% |
| BeyondSpring Inc. | 24.86 Million USD | -1692.628% |
| Synlogic, Inc. | 58.53 Million USD | -661.527% |
| Allarity Therapeutics, Inc. | 17.89 Million USD | -2391.264% |
| Phio Pharmaceuticals Corp. | 4.49 Million USD | -9822.907% |
| Peak Bio, Inc. | 1249.13 USD | -35683695.922% |
| Werewolf Therapeutics, Inc. | 60.44 Million USD | -637.414% |
| Krystal Biotech, Inc. | 160.42 Million USD | -177.846% |
| Karyopharm Therapeutics Inc. | 270.63 Million USD | -64.703% |
| SpringWorks Therapeutics, Inc. | 348.03 Million USD | -28.071% |
| Lipella Pharmaceuticals Inc. | 2.15 Million USD | -20567.222% |
| MannKind Corporation | 125.59 Million USD | -254.895% |
| Ikena Oncology, Inc. | 84.57 Million USD | -427.019% |
| Cyclerion Therapeutics, Inc. | 9.64 Million USD | -4520.473% |
| Gyre Therapeutics, Inc. | 89.6 Million USD | -397.469% |
| Gossamer Bio, Inc. | 183.75 Million USD | -142.566% |
| CohBar, Inc. | 12.38 Million USD | -3498.049% |
| Cognition Therapeutics, Inc. | 50.72 Million USD | -778.75% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -1516.043% |
| Legend Biotech Corporation | 583.14 Million USD | 23.563% |
| Mural Oncology plc | 192.07 Million USD | -132.069% |
| Biora Therapeutics, Inc. | 67.14 Million USD | -563.823% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | -2660.79% |
| Disc Medicine, Inc. | 91.12 Million USD | -389.149% |
| Champions Oncology, Inc. | 28.11 Million USD | -1485.688% |
| REGENXBIO Inc. | 321.15 Million USD | -38.791% |
| Ensysce Biosciences, Inc. | 5.36 Million USD | -8214.075% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -699.442% |
| Cellectar Biosciences, Inc. | 38.96 Million USD | -1044.07% |
| Edgewise Therapeutics, Inc. | 114.35 Million USD | -289.777% |
| Vaxart, Inc. | 90.72 Million USD | -391.3% |
| PharmaCyte Biotech, Inc. | 8.52 Million USD | -5131.65% |
| Aldeyra Therapeutics, Inc. | 42.79 Million USD | -941.586% |
| Cellectis S.A. | 97.32 Million USD | -358.012% |
| Longeveron Inc. | 21.25 Million USD | -1997.586% |
| Repare Therapeutics Inc. | 167.35 Million USD | -166.339% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 67.245% |
| Inozyme Pharma, Inc. | 75.64 Million USD | -489.248% |
| Revolution Medicines, Inc. | 498.76 Million USD | 10.632% |
| Nymox Pharmaceutical Corporation | 6.65 Million USD | -6600.797% |
| Third Harmonic Bio, Inc. | 43.95 Million USD | -914.099% |
| ArriVent BioPharma, Inc. Common Stock | 74.59 Million USD | -497.583% |
| AN2 Therapeutics, Inc. | 69.63 Million USD | -540.105% |
| Anixa Biosciences, Inc. | 11.06 Million USD | -3930.172% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 90.665% |
| Denali Therapeutics Inc. | 527.23 Million USD | 15.457% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -5049.062% |
| Veru Inc. | 101.34 Million USD | -339.808% |
| Corvus Pharmaceuticals, Inc. | 23.4 Million USD | -1804.289% |
| Cingulate Inc. | 22.75 Million USD | -1858.492% |
| Passage Bio, Inc. | 108.38 Million USD | -311.238% |
| Context Therapeutics Inc. | 25.07 Million USD | -1677.784% |
| Exicure, Inc. | 14.07 Million USD | -3066.645% |
| Day One Biopharmaceuticals, Inc. | 206.06 Million USD | -116.31% |
| Oramed Pharmaceuticals Inc. | 43.3 Million USD | -929.392% |
| Scinai Immunotherapeutics Ltd. | 9.17 Million USD | -4756.957% |
| Rhythm Pharmaceuticals, Inc. | 252.48 Million USD | -76.541% |
| Nuvalent, Inc. | 149.49 Million USD | -198.168% |
| ABVC BioPharma, Inc. | 8.06 Million USD | -5425.504% |
| Carisma Therapeutics, Inc. | 103.65 Million USD | -330.041% |
| Unicycive Therapeutics, Inc. | 21.44 Million USD | -1978.125% |
| OmniAb, Inc. | 83.89 Million USD | -431.303% |
| Anew Medical, Inc. | 1.3 Million USD | -34165.295% |
| Fennec Pharmaceuticals Inc. | 32.76 Million USD | -1260.447% |
| Lipocine Inc. | 15.08 Million USD | -2855.788% |
| Lexeo Therapeutics, Inc. Common Stock | 68.51 Million USD | -550.587% |
| Nautilus Biotechnology, Inc. | 76.15 Million USD | -485.325% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -1005.655% |
| G1 Therapeutics, Inc. | 114.84 Million USD | -288.127% |
| Bellerophon Therapeutics, Inc. | 22.38 Million USD | -1891.32% |
| Sage Therapeutics, Inc. | 664.14 Million USD | 32.886% |
| Ocugen, Inc. | 71.56 Million USD | -522.825% |
| Mind Medicine (MindMed) Inc. | 93.86 Million USD | -374.865% |
| Q32 Bio Inc. | 92.68 Million USD | -380.942% |
| Brainstorm Cell Therapeutics Inc. | 21.17 Million USD | -2005.115% |
| Alumis Inc. Common Stock | 158.17 Million USD | -181.802% |
| Equillium, Inc. | 50.6 Million USD | -780.799% |
| Kyverna Therapeutics, Inc. | 62.4 Million USD | -614.253% |
| Coya Therapeutics, Inc. | 13.9 Million USD | -3105.46% |
| CNS Pharmaceuticals, Inc. | 18.86 Million USD | -2262.759% |
| Galera Therapeutics, Inc. | 46.95 Million USD | -849.366% |
| Evelo Biosciences, Inc. | 108.46 Million USD | -310.946% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -3496.763% |
| Dominari Holdings Inc. | 23.83 Million USD | -1770.094% |
| Edesa Biotech, Inc. | 9.22 Million USD | -4733.012% |
| vTv Therapeutics Inc. | 11.9 Million USD | -3643.487% |
| Bio-Techne Corporation | 563.03 Million USD | 20.834% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | -9.034% |
| Harmony Biosciences Holdings, Inc. | 268.75 Million USD | -65.852% |
| Prelude Therapeutics Incorporated | 132.27 Million USD | -236.972% |
| Candel Therapeutics, Inc. | 14.41 Million USD | -2993.033% |
| iTeos Therapeutics, Inc. | 163.69 Million USD | -172.296% |
| Nkarta, Inc. | 131.65 Million USD | -238.577% |
| BioCardia, Inc. | 12.12 Million USD | -3577.395% |
| Iterum Therapeutics plc | 47.46 Million USD | -839.026% |